Objectives: The carbapenemase OXA-48 has been reported from different Mediterranean countries. It is mostly encoded on a single plasmid in various Enterobacteriaceae species. We characterized the epidemiological and molecular features of OXA-48-producing Enterobacteriaceae (OPE) in Israel.
Introduction
OXA-48 is one of the few Ambler class D, carbapenemhydrolysing b-lactamases that have been identified in Enterobacteriaceae 1 and is the most commonly reported. First identified in Turkey in 2001, 2 OXA-48-producing Enterobacteriaceae (OPE) have since been reported from several countries in the Middle East, North Africa and Europe. 3, 4 The bla OXA-48 gene has been detected in a variety of Enterobacteriaceae species and clones, but a common feature in almost all isolates is the location of the gene inside the Tn1999 transposon within a 70 kb plasmid. 1, 4 Since 2006, resistance to carbapenems in Enterobacteriaceae in Israel has been caused mainly by a single clone of KPCproducing Klebsiella pneumoniae, believed to have been imported from the USA in late 2005. 5 Here we describe the epidemiology and molecular characteristics of OPE infection identified in Israel since 2007. 6 
Methods

Patients and isolates
Patients were identified following detection of bla OXA-48 -harbouring Enterobacteriaceae as part of ongoing activity of the Israeli National Center for Infection Control. Rectal surveillance cultures were done as previously described. 7 Patients' data were collected as part of the epidemiological investigation. The study was approved by the Ethics Committee of the Tel-Aviv Medical Center, Tel-Aviv, Israel.
Phenotypic and molecular characterization of isolates
Identification and antimicrobial susceptibility testing was performed using the VITEK-2 system (bioMérieux, Marcy l'Étoile, France). Ertapenem, imipenem and meropenem MICs were verified by Etest (AB Biodisk, Solna, Sweden). Phenotypic characterization comprised the extended-spectrum b-lactamase (ESBL) double-disc test, the modified Hodge test (MHT) and the boronic acid, EDTA and dipicolinic acid assays. 8 Isolates were 
Plasmid analysis
Plasmid DNA purified from the five isolates was transformed into E. coli DH10B. Transformants were selected on LB agar supplemented with 100 mg/L ampicillin and confirmed by bla OXA-48 PCR. Determination of plasmid size and restriction fragment length polymorphism (RFLP) were done as previously described. 15 The plasmid incompatibility group (Inc) was determined using a PCR-based replicon typing method 16 and repP PCR 1 The genetic environment of the bla OXA-48 gene was studied by PCR and sequencing as previously described. 1 
Conjugation experiments
Conjugation was tested using a filter mating experiment. 17 We used E. coli isolates 6537 and 4360A, the Klebsiella oxytoca isolate 3439 and the K. pneumoniae isolate 4360B as donors, and E. coli HB101, a streptomycinresistant strain, as the recipient. Streptomycin (500 mg/L) and ampicillin (32 mg/L) (for intra-species conjugation) or cefazolin (8 mg/L) (for interspecies conjugation) were used to select against the donor or recipient strains, respectively. Conjugation efficiency of the bla OXA-48 -carrying plasmid was compared with that of the pKpQIL plasmid. This plasmid was chosen as it is the main bla KPC-3 -carrying plasmid found in the epidemic K. pneumoniae clone in Israel, sequence type (ST) 258. 5 It was also identified in isolate 2112, a clinical E. coli strain 15 that was used as a donor in our experiment. Conjugation efficiency was calculated as the number of transconjugants per recipient cell.
Results
Clinical and demographic features of OPE-infected patients
Clinical and demographic features of the four OPE-infected patients are summarized in Table 1 . The first patient, a Jordanian woman referred to our hospital for oncological care, was diagnosed with an OXA-48-producing E. coli bacteraemia, successfully treated with ceftazidime and colistin. The second patient was a resident of the city of Qalqylia, in the Palestinian Authority. He was diagnosed with cholangiocarcinoma and underwent cholecystectomy on May 2010 at a hospital in Amman, Jordan. In August 2010 he was transferred to a hospital in Jerusalem. On the day after transfer he developed K. oxytoca sepsis and was treated successfully with meropenem and colistin. In Patients 3 and 4, OPE were detected in rectal culture as part of either routine admission surveillance (Patient 3) or contact investigation (Patient 4). Following the detection of the OXA-48-producing E. coli in patient 3, the entire ward in the facility (40 patients) was surveyed for the presence of OPE by rectal swabs, 7 yielding negative results. Patient 4 was hospitalized for 3 days for control of hypertension and was surveyed as part of an unrelated contact investigation. She had never been hospitalized outside of Israel, but had made frequent visits to Jordan.
Microbiological and molecular characteristics of OPE strains and bla OXA-48 -carrying plasmids All isolates yielded a positive MHT and a negative ESBL double-disc test (except 6537) and negative boronic acid, EDTA and dipicolinic acid assays. PCR was positive for the bla OXA-48 gene in all isolates. All isolates and their respective transformants (T), except E. coli 6537, were susceptible to ceftriaxone and ceftazidime but had elevated MICs of ertapenem and imipenem (Table 2) . Isolate E. coli 6537, but not 6537T, tested positive for the bla CTX-M-15 gene. The MICs of ertapenem and imipenem for all the isolates and their corresponding transformants were similar, with the exception of those for E. coli 1736, which showed decreased OmpC expression. 6 MLST of the E. coli strains showed a clonally diverse population (STs 167, 1431 and 2139).
Plasmid analysis of all five bla OXA-48 -harbouring isolates and their respective transformants revealed one band of approximately 60 kb, identical in all (Figure S1a 
Conjugation studies
bla OXA-48 -carrying plasmids from all isolates were able to undergo both intra-and inter-species self-conjugation. Intra- 
Discussion
This report highlights the role of medical tourism as a main route for the introduction of OPE to Israel; three of the four patients (Patients 1 -3) were hospitalized outside of Israel (two in Jordan and one in Georgia) prior to the detection of an OPE infection. In the fourth patient, the acquisition could not be traced to healthcare exposure, raising the possibility of community acquisition, possibly during one of her frequent trips to Jordan. Interestingly, she was a carrier of OXA-48-producing K. pneumoniae ST101, as previously reported from Tunisia 4 and Spain. 18 Our study demonstrates the presence of the bla OXA-48 gene inside Tn1999.2, in an identical 60 kb plasmid in various E. coli and Klebsiella spp. isolates. The repP gene, detected in the previously described 70 kb plasmid, 1 was not detected in our plasmid. A recent report from Tunisia identified two types of 70 kb, bla OXA-48 -carrying plasmids, one presenting the IncA/C group and the other undetermined. 19 Hence, it appears that bla OXA-48 -carrying plasmids are not identical, and may vary in their Inc group.
Unlike bla KPC-3 , which has spread mainly in a single epidemic K. pneumoniae clone (ST258), 5 the spread of the bla OXA-48 gene is likely to be facilitated by the transfer of plasmids. 1 The conjugation experiments performed have demonstrated that (i) the bla OXA-48 -carrying plasmid identified here is capable of interspecies conjugation, as previously described, 1 and (ii) its conjugation efficiency is 10000 times higher than that of pKpQIL, the bla KPC-3 -carrying plasmid. These differences in conjugation frequencies may help to improve our understanding of the different ways in which different carbapenemases spread. As knowledge regarding the prevalence of resistant organisms in certain countries may be lacking, admission screening for resistant organisms of all patients who have received medical care in foreign countries may be prudent.
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